Key result
Extended aldosterone synthase inhibition sustains blood pressure and aldosterone-to-renin ratio reductions for 2 years.
Why the study?
Does an extended course of aldosterone synthase inhibition produce persistent reductions in blood pressure and the aldosterone-to-renin ratio in patients with hypertension due to primary aldosteronism?
Does an extended course of aldosterone synthase inhibition produce persistent reductions in blood pressure and the aldosterone-to-renin ratio in patients with hypertension due to primary aldosteronism?
An extended course of aldosterone synthase inhibition may induce durable 2-year remission of hypertension and biochemical hyperaldosteronism in patients with primary aldosteronism even after treatment cessation.
Answers are grounded in this paper and cite their sources.
May support sustained remission in primary aldosteronism; leaves open confirmation by randomized trials.
Among patients with hypertension due to primary aldosteronism, reductions in blood pressure and the aldosterone-to-renin ratio persisted for 2 years after completion of an extended course of aldosterone synthase inhibition.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2026) studied this question. Extended aldosterone synthase inhibition produced reductions in blood pressure and the aldosterone-to-renin ratio that persisted for 2 years in patients with primary aldosteronism.
Synapse has enriched 10 related papers. Consider them for comparative context: